Polycystic Ovarian Syndrome

Women's Health
4
Pipeline Programs
3
Companies
2
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
CETRORELIX ACETATEApproved
cetrorelix acetate
Unknown Company
subcutaneous2024
U
CETROTIDEApproved
cetrorelix acetate
Unknown Company
subcutaneous2000

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
1
MenotropinPhase 41 trial
Active Trials
NCT00805935Completed110Est. Sep 2010
M&
Merck & Co.RAHWAY, NJ
1 program
1
Cetrorelix acetatePhase 31 trial
Active Trials
NCT01185704CompletedEst. Feb 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsMenotropin
Merck & Co.Cetrorelix acetate

Clinical Trials (2)

Total enrollment: 110 patients across 2 trials

NCT00805935Ferring PharmaceuticalsMenotropin

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

Start: Jan 2009Est. completion: Sep 2010110 patients
Phase 4Completed
NCT01185704Merck & Co.Cetrorelix acetate

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

Start: Nov 2008Est. completion: Feb 2012
Phase 3Completed

Related Jobs in Women's Health

Senior Medical Science Liaison

Ferring Pharmaceuticals
Bangkok, Thailand
20h ago

Senior Key Account Manager

Ferring Pharmaceuticals
Bucureşti, Romania
1w ago

Territory Representative - Miami

Caldera Medical
Miami, FL, US
1w ago

Sales Representative Gynecological Health

Medtronic
Malaga, Andalucia, Spain
1w ago

Sales Representative, Women's Health - Charleston, SC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Sales Representative, Women's Health- Charlotte, NC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space

Related Indications

Endometriosis(43)Menopause(27)Polycystic Ovary Syndrome(14)Postmenopause(8)Controlled Ovarian Stimulation(5)Vasomotor Symptoms Associated With Menopause(4)Preeclampsia(3)Uterine Fibroids(3)Uterine Leiomyomata (Fibroids)(3)Ovarian Hyperstimulation Syndrome(3)